ArticleCureus2024
Impact of Vaccination Time on Anti-SARS-CoV-2 Antibody Levels in Adults: A Quasi-experimental Study.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Circadian clocks and adaptive immune function: from mechanisms to therapeutic applications.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimVaccination time may provide an opportunity to advance immunogenicity in terms of the immune system's circadian nature. This analytical study was planned to determine the impact of forenoon and afternoon administration of the COVID-19 vaccine to adults on the magnitude of antibody response.
methodA total of 33 healthy adults with no history of COVID-19 infection or any other disease participated in the study. They were allotted a forenoon (900-1200 hours) or afternoon (1200-500 hours) slot for vaccination. They were categorized as a forenoon or afternoon group, with 16 subjects in the forenoon and 17 in the afternoon group. With the consent of the participants, a blood sample was collected before vaccination, 30 days after the first and 30 days after the second dose of vaccination from all the subjects. The antibody titer response was measured using a commercial semi-quantitative assay, SARS-CoV-2 IgG II.
resultsThe baseline antibody titer against COVID-19 was 51.41 ± 22.22 AU/mL and 53.21 ± 15.67 AU/mL in the forenoon and afternoon groups, respectively, which increased to 15773.00 ± 3231.41 AU/mL and 12970.82 ± 7608.00 AU/mL after 30 days of the first dose of the COVID-19 vaccine in the forenoon and afternoon groups, respectively. This further increased to 37007.00 ± 1697.75 AU/mL and 38012.00 ± 14001.16 AU/mL after 30 days of the second dose of the COVID-19 vaccine in the forenoon and afternoon groups, respectively. There was no difference in antibody response in subjects with forenoon and afternoon vaccinations. There was no significant difference in antibody titer in males vs. females. The study reported that antibody titers decreased with increasing age and BMI of participants.
conclusionThe time of the day of vaccination does not impact the immune response to COVID-19, but age and BMI are important factors to consider during vaccination against SARS-CoV-2 in the adult population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.